IP Library Granted Patent US 9,655,953
Granted Patent B2
US 9,655,953 · App. 14/516,231 · Granted May 23, 2017

Targeted protein replacement for the treatment of lysosomal storage disorders

Inventors: Silvia Muro Galindo (Silver Spring, MD); Vladimir R. Muzykantov (Bryn Athyn, PA); Edward Howard Schuchman (Haworth, NJ)
Assignees: Icahn School of Medicine at Mount Sinai; The Trustees of the University of Pennsylvania
A61K38/465A61K47/48561C07K16/2821C12N9/16A61K38/00C07K2317/77C07K2319/035C12Y301/04012Y10T428/2982Y10T428/2991
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,655,953
App. No.
14/516,231
Granted
May 23, 2017
Kind
B2
Abstract

The present invention relates to compositions and methods for delivering lysosomal proteins. The compositions and methods described herein permit the targeted delivery of exogenous lysosomal proteins to cell surface proteins that allow their internalization via non-clathrin pathways. The present invention further relates to the use of the compositions and methods for enzyme replacement therapy of lysosomal storage diseases. Nucleic acids, recombinant cells and kits useful for making and using the compositions of the invention are also provided.

Claims (7)

1. A nucleic acid comprising a nucleotide sequence encoding a fusion protein comprising a mammalian acid sphingomyelinase or active fragment thereof covalently attached to a targeting moiety, wherein the targeting moiety binds to an extracellular portion of Intracellular Adhesion Molecule-1 (ICAM-1) or Platelet Endothelial Cell Adhesion Molecule (PECAM-1).

2. The nucleic acid of claim 1 in which the nucleotide sequence is operably linked to a promoter.

3. An isolated host cell which comprises in its genome the nucleic acid of claim 1 .

4. A method for producing a fusion protein comprising a mammalian acid sphingomyelinase or active fragment thereof which is covalently attached to a targeting moiety, wherein the targeting moiety binds to an extracellular portion of Intracellular Adhesion Molecule-1 (ICAM-1) or Platelet Endothelial Cell Adhesion Molecule (PECAM-1), said method comprising:

(a) culturing the isolated host cell of claim 3 under conditions in which the mammalian acid sphingomyelinase or active fragment covalently attached to the targeting moiety is expressed and

(b) recovering the expressed mammalian acid sphingomyelinase or active fragment covalently attached to the targeting moiety.

5. The method of claim 4 , in which the isolated host cell is a mammalian cell in culture.

Assignments (4)
CHANGE OF NAME Recorded Apr 29, 2016
From: MOUNT SINAI SCHOOL OF MEDICINE
To: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Reel/Frame 038582/0470 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2016
From: SCHUCHMAN, EDWARD HOWARD
To: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY
Reel/Frame 038201/0835 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2016
From: GALINDO, SILVIA MURO; MUZYKANTOV, VLADIMIR R.
To: UNIVERSITY OF PENNSYLVANIA
Reel/Frame 038201/0942 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2016
From: UNIVERSITY OF PENNSYLVANIA
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 038202/0115 →
Continuity (3)
Continuation 11631248
Provisional Application 60584648 · Jul 1, 2004
Related Publication 20150132368A1 · May 14, 2015